{"id":"doi:10.1016/j.arr.2024.102348","kind":"review","title":"Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit","authors":["Poul Flemming Høilund‐Carlsen","Abass A. Alavi","Jorge R. Barrio","Rudolph J. Castellani","Tommaso Costa","Karl Herrup","Kasper P. Kepp","Rachael L. Neve","George L. Perry","Mona-Elisabeth R. Revheim","Nikolaos K. R K Robakis","Stefano Luca Sensi","Bryce Vissel"],"author_count":13,"year":2024,"published":"2024-06-01","venue":"Ageing Research Reviews","cited_by":40,"doi":"10.1016/j.arr.2024.102348","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1016/j.arr.2024.102348","archive_url":"https://space-kitty.com/papers/doi:10.1016/j.arr.2024.102348","updated":null,"pmid":"38830549","pmcid":null,"openalex_id":"W4399258296","pdf_url":null,"abstract":null,"abstract_license":null,"license":"cc-by-nc-nd","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Alzheimer's disease research and treatments"],"details":null,"provenance":"openalex","attribution":"Metadata and citation counts: OpenAlex (CC0).","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}